O	O	O	0	8	Abnormal	Abnormal	B-NP	JJ	O	4	NMOD	O
O	O	O	9	10	T	T	I-NP	NN	O	4	NMOD	O
O	O	O	11	21	lymphocyte	lymphocyte	I-NP	NN	O	4	NMOD	O
O	O	O	22	33	development	development	I-NP	NN	O	0	ROOT	O
O	O	O	34	41	induced	induce	B-VP	VBN	O	4	NMOD	O
O	O	O	42	44	by	by	B-PP	IN	O	5	VMOD	O
O	O	O	45	53	targeted	target	B-NP	VBN	O	8	NMOD	O
O	O	O	54	68	overexpression	overexpression	I-NP	NN	O	6	PMOD	O
O	O	O	69	71	of	of	B-PP	IN	O	8	NMOD	O
T1	B-Protein	B-Protein	72	79	IkappaB	IkappaB	B-NP	NN	B-protein	11	NMOD	B-protein
T1	I-Protein	I-Protein	80	85	alpha	alpha	I-NP	NN	I-protein	9	PMOD	I-protein
O	O	O	85	86	.	.	O	.	O	4	P	O

O	O	O	88	89	A	A	B-NP	DT	O	2	NMOD	O
O	O	O	90	94	role	role	I-NP	NN	O	14	SUB	O
O	O	O	95	97	in	in	B-PP	IN	O	2	NMOD	O
O	O	O	98	104	thymic	thymic	B-NP	JJ	O	5	NMOD	O
O	O	O	105	115	maturation	maturation	I-NP	NN	O	3	PMOD	O
O	O	O	116	119	for	for	B-PP	IN	O	2	NMOD	O
O	O	O	120	127	factors	factor	B-NP	NNS	O	6	PMOD	O
O	O	O	128	130	of	of	B-PP	IN	O	7	NMOD	O
O	O	O	131	134	the	the	B-NP	DT	O	13	NMOD	O
O	O	O	135	137	NF	NF	I-NP	NN	B-protein	13	NMOD	B-protein
O	O	O	137	138	-	-	B-NP	HYPH	I-protein	13	NMOD	I-protein
O	O	O	138	144	kappaB	kappaB	I-NP	NN	I-protein	13	NMOD	I-protein
O	O	O	145	151	family	family	I-NP	NN	I-protein	8	PMOD	I-protein
O	O	O	152	155	has	have	B-VP	VBZ	O	0	ROOT	O
O	O	O	156	160	long	long	I-VP	RB	O	14	VMOD	O
O	O	O	161	165	been	be	I-VP	VBN	O	14	VC	O
O	O	O	166	175	suspected	suspect	I-VP	VBN	O	16	VC	O
O	O	O	175	176	,	,	O	,	O	17	P	O
O	O	O	177	180	but	but	O	CC	O	17	VMOD	O
O	O	O	181	184	not	not	B-VP	RB	O	22	VMOD	O
O	O	O	185	188	yet	yet	I-VP	RB	O	20	AMOD	O
O	O	O	189	195	proven	prove	I-VP	VBN	O	17	VMOD	O
O	O	O	195	196	.	.	O	.	O	14	P	O

O	O	O	197	207	Transgenic	Transgenic	B-NP	JJ	O	2	NMOD	O
O	O	O	208	212	mice	mouse	I-NP	NNS	O	14	SUB	O
O	O	O	213	217	with	with	B-PP	IN	O	2	NMOD	O
O	O	O	218	219	a	a	B-NP	DT	O	8	NMOD	O
O	O	O	220	230	lymphocyte	lymphocyte	I-NP	NN	B-cell_type	8	NMOD	B-cell_type
O	O	O	230	231	-	-	B-NP	HYPH	O	8	NMOD	O
O	O	O	231	239	specific	specific	I-NP	JJ	O	8	NMOD	O
O	O	O	240	246	defect	defect	I-NP	NN	O	3	PMOD	O
O	O	O	247	249	in	in	B-PP	IN	O	8	NMOD	O
T3	B-Entity	B-Entity	250	252	NF	NF	B-NP	NN	B-protein	12	NMOD	B-protein
T3	I-Entity	I-Entity	252	253	-	-	B-NP	HYPH	I-protein	12	NMOD	I-protein
T3	I-Entity	I-Entity	253	259	kappaB	kappaB	I-NP	NN	I-protein	13	NMOD	I-protein
O	O	O	260	270	activation	activation	I-NP	NN	O	9	PMOD	O
O	O	O	271	275	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	276	284	produced	produce	I-VP	VBN	O	14	VC	O
O	O	O	285	287	by	by	B-PP	IN	O	15	VMOD	O
O	O	O	288	296	targeted	target	B-NP	VBN	O	18	NMOD	O
O	O	O	297	307	expression	expression	I-NP	NN	O	16	PMOD	O
O	O	O	308	310	of	of	B-PP	IN	O	18	NMOD	O
O	O	O	311	316	human	human	B-NP	JJ	B-protein	22	NMOD	B-protein
T2	B-Protein	B-Protein	317	324	IkappaB	IkappaB	I-NP	NN	I-protein	22	NMOD	I-protein
T2	I-Protein	I-Protein	325	330	alpha	alpha	I-NP	NN	I-protein	19	PMOD	I-protein
O	O	O	330	331	.	.	O	.	O	14	P	O

O	O	O	332	335	The	The	B-NP	DT	O	3	NMOD	O
O	O	O	336	342	thymic	thymic	I-NP	JJ	O	3	NMOD	O
O	O	O	343	354	cellularity	cellularity	I-NP	NN	O	7	SUB	O
O	O	O	355	357	of	of	B-PP	IN	O	3	NMOD	O
O	O	O	358	363	these	these	B-NP	DT	O	6	NMOD	O
O	O	O	364	368	mice	mouse	I-NP	NNS	O	4	PMOD	O
O	O	O	369	372	was	be	B-VP	VBD	O	0	ROOT	O
O	O	O	373	386	significantly	significantly	I-VP	RB	O	7	VMOD	O
O	O	O	387	396	decreased	decrease	I-VP	VBN	O	7	VC	O
O	O	O	396	397	.	.	O	.	O	7	P	O

O	O	O	398	401	The	The	B-NP	DT	O	2	NMOD	O
O	O	O	402	412	proportion	proportion	I-NP	NN	O	12	SUB	O
O	O	O	413	415	of	of	B-PP	IN	O	2	NMOD	O
O	O	O	416	422	mature	mature	B-NP	JJ	O	6	AMOD	O
O	O	O	422	423	,	,	I-NP	,	O	6	P	O
O	O	O	424	431	TCRhigh	TCRhigh	I-NP	JJ	B-cell_type	7	NMOD	B-cell_type
O	O	O	432	442	thymocytes	thymocyte	I-NP	NNS	I-cell_type	3	PMOD	I-cell_type
O	O	O	443	445	of	of	B-PP	IN	O	7	NMOD	O
O	O	O	446	449	the	the	B-NP	DT	O	11	NMOD	O
O	O	O	450	459	alphabeta	alphabeta	I-NP	NN	B-cell_type	11	NMOD	B-cell_type
O	O	O	460	467	lineage	lineage	I-NP	NN	I-cell_type	8	PMOD	I-cell_type
O	O	O	468	471	was	be	B-VP	VBD	O	20	VMOD	O
O	O	O	472	479	reduced	reduce	I-VP	VBN	O	12	VC	O
O	O	O	479	480	,	,	O	,	O	20	P	O
O	O	O	481	484	and	and	O	CC	O	20	VMOD	O
O	O	O	485	488	the	the	B-NP	DT	O	19	NMOD	O
O	O	O	489	498	remaining	remain	I-NP	VBG	O	19	NMOD	O
O	O	O	499	506	TCRhigh	TCRhigh	I-NP	JJ	B-cell_type	19	NMOD	B-cell_type
O	O	O	507	517	population	population	I-NP	NN	I-cell_type	20	SUB	I-cell_type
O	O	O	518	527	contained	contain	B-VP	VBD	O	0	ROOT	O
O	O	O	528	530	an	an	B-NP	DT	O	24	NMOD	O
O	O	O	531	540	unusually	unusually	I-NP	RB	O	23	AMOD	O
O	O	O	541	545	high	high	I-NP	JJ	O	24	NMOD	O
O	O	O	546	556	proportion	proportion	I-NP	NN	O	20	OBJ	O
O	O	O	557	559	of	of	B-PP	IN	O	24	NMOD	O
O	O	O	560	566	double	double	B-NP	JJ	B-cell_line	29	NMOD	B-cell_line
O	O	O	566	567	-	-	I-NP	HYPH	I-cell_line	29	NMOD	I-cell_line
O	O	O	567	575	positive	positive	I-NP	JJ	I-cell_line	29	NMOD	I-cell_line
O	O	O	576	581	cells	cell	I-NP	NNS	I-cell_line	25	PMOD	I-cell_line
O	O	O	581	582	.	.	O	.	O	20	P	O

O	O	O	583	587	This	This	B-NP	DT	O	2	NMOD	O
O	O	O	588	594	defect	defect	I-NP	NN	O	5	SUB	O
O	O	O	595	597	in	in	B-PP	IN	O	2	NMOD	O
O	O	O	598	608	maturation	maturation	B-NP	NN	O	3	PMOD	O
O	O	O	609	617	resulted	result	B-VP	VBD	O	0	ROOT	O
O	O	O	618	620	in	in	B-PP	IN	O	5	VMOD	O
O	O	O	621	622	a	a	B-NP	DT	O	9	NMOD	O
O	O	O	623	632	transgene	transgene	I-NP	NN	O	9	NMOD	O
O	O	O	633	637	dose	dose	I-NP	NN	O	12	NMOD	O
O	O	O	637	638	-	-	B-NP	HYPH	O	12	NMOD	O
O	O	O	638	647	dependent	dependent	I-NP	JJ	O	12	NMOD	O
O	O	O	648	657	reduction	reduction	I-NP	NN	O	6	PMOD	O
O	O	O	658	660	in	in	B-PP	IN	O	12	NMOD	O
O	O	O	661	671	peripheral	peripheral	B-NP	JJ	B-cell_type	16	NMOD	B-cell_type
O	O	O	672	673	T	T	I-NP	NN	I-cell_type	16	NMOD	I-cell_type
O	O	O	674	685	lymphocytes	lymphocyte	I-NP	NNS	I-cell_type	13	PMOD	I-cell_type
O	O	O	685	686	,	,	O	,	O	5	P	O
O	O	O	687	691	with	with	B-PP	IN	O	5	VMOD	O
O	O	O	692	695	the	the	B-NP	DT	O	21	NMOD	O
T4	B-Entity	B-Entity	696	699	CD8	CD8	I-NP	NN	B-cell_type	21	NMOD	B-cell_type
O	O	O	700	707	lineage	lineage	I-NP	NN	I-cell_type	22	SUB	I-cell_type
O	O	O	708	713	being	be	B-VP	VBG	O	18	PMOD	O
O	O	O	714	718	more	more	I-VP	RBR	O	24	AMOD	O
O	O	O	719	727	severely	severely	I-VP	RB	O	22	VMOD	O
O	O	O	728	736	affected	affect	I-VP	VBN	O	22	VC	O
O	O	O	736	737	.	.	O	.	O	5	P	O

O	O	O	738	743	These	These	B-NP	DT	O	2	NMOD	O
O	O	O	744	748	data	datum	I-NP	NNS	O	3	SUB	O
O	O	O	749	756	provide	provide	B-VP	VBP	O	0	ROOT	O
O	O	O	757	763	direct	direct	B-NP	JJ	O	5	NMOD	O
O	O	O	764	772	evidence	evidence	I-NP	NN	O	3	OBJ	O
O	O	O	773	776	for	for	B-PP	IN	O	5	NMOD	O
O	O	O	777	780	the	the	B-NP	DT	O	8	NMOD	O
O	O	O	781	792	involvement	involvement	I-NP	NN	O	6	PMOD	O
O	O	O	793	795	of	of	B-PP	IN	O	8	NMOD	O
T5	B-Entity	B-Entity	796	798	NF	NF	B-NP	NN	B-protein	12	NMOD	B-protein
T5	I-Entity	I-Entity	798	799	-	-	B-NP	HYPH	I-protein	12	P	I-protein
T5	I-Entity	I-Entity	799	805	kappaB	kappaB	I-NP	NN	I-protein	16	NMOD	I-protein
O	O	O	805	806	/	/	I-NP	SYM	O	16	P	O
O	O	O	806	809	Rel	Rel	I-NP	NN	B-protein	16	NMOD	B-protein
O	O	O	810	816	family	family	I-NP	NN	I-protein	16	NMOD	I-protein
O	O	O	817	825	proteins	protein	I-NP	NNS	I-protein	9	PMOD	I-protein
O	O	O	826	828	in	in	B-PP	IN	O	8	NMOD	O
O	O	O	829	833	late	late	B-NP	JJ	O	19	NMOD	O
O	O	O	834	840	stages	stage	I-NP	NNS	O	17	PMOD	O
O	O	O	841	843	of	of	B-PP	IN	O	19	NMOD	O
O	O	O	844	845	T	T	B-NP	NN	B-cell_type	23	NMOD	B-cell_type
O	O	O	846	856	lymphocyte	lymphocyte	I-NP	NN	I-cell_type	23	NMOD	I-cell_type
O	O	O	857	868	development	development	I-NP	NN	O	20	PMOD	O
O	O	O	868	869	,	,	O	,	O	3	P	O
O	O	O	870	880	coincident	coincident	B-ADJP	JJ	O	3	VMOD	O
O	O	O	881	885	with	with	B-PP	IN	O	25	AMOD	O
O	O	O	886	894	positive	positive	B-NP	JJ	O	30	NMOD	O
O	O	O	895	898	and	and	I-NP	CC	O	30	NMOD	O
O	O	O	899	907	negative	negative	I-NP	JJ	O	30	NMOD	O
O	O	O	908	917	selection	selection	I-NP	NN	O	26	PMOD	O
O	O	O	917	918	.	.	O	.	O	3	P	O
